Thalidomide

Catalog No.S1193

Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.Phase 3.

Price Stock Quantity  
In DMSO USD 190 In stock
USD 147 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Thalidomide Chemical Structure

Thalidomide Chemical Structure
Molecular Weight: 258.23

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Thalidomide is available in the following compound libraries:

Product Information

  • Compare TNF-alpha Inhibitors
    Compare TNF-alpha Inhibitors
  • Research Area

Product Description

Biological Activity

Thalidomide was introduced as a sedative drug in the late 1950s. However, it was withdrawn due to a teratogenic effect on fetal development. Thalidomide binds to inactivate the protein cereblon, which is important to limb formation. [1]
There is now a growing clinical interest in thalidomide since it is introduced as an immunomodulatory agent used primarily, combined with dexamethasone, to treat multiple myeloma. The combination of thalidomide and dexamethasone, often in combination with melphalan, is now one of the most common regimens for patients with newly diagnosed multiple myeloma, with an improved response rate of up to 60-70%. [1]

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01927718 Not yet recruiting Myeloma M.D. Anderson Cancer Center|Celgene Corporation 2014-02
NCT01889420 Not yet recruiting Multiple Myeloma in Relapse New Mexico Cancer Care Alliance|Novartis Corporation 2014-02 Phase 1
NCT02018523 Not yet recruiting Carcinoma, Non-Small-Cell Lung Baylor College of Medicine|Jun Zhang|Celgene Corporation 2014-02 Phase 1
NCT01946152 Not yet recruiting Myeloma M.D. Anderson Cancer Center|Celgene Corporation 2014-02 Phase 1|Phase 2
NCT01996865 Not yet recruiting Lymphoma, Non-Hodgkin Celgene Corporation 2014-02 Phase 3

Chemical Information

Download Thalidomide SDF
Molecular Weight (MW) 258.23
Formula

C13H10N2O4

CAS No. 50-35-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms Thalomid
Solubility (25°C) * In vitro DMSO 52 mg/mL (201 mM)
Water <1 mg/mL (<1 mM)
Ethanol 2 mg/mL (7 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.25823 2.5823 5.1646 7.7469

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related TNF-alpha Inhibitors

  • Necrostatin-1

    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

    Features:A powerful tool for characterizing the role of necroptosis with characterized primary target.

  • ABT-199 (GDC-0199)

    ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 2.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • Birinapant

    Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP. Phase 1/2.

  • Lenalidomide (CC-5013)

    Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

  • Pomalidomide

    Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.

    Features:A derivative of thalidomide and up to 10,000 times more potent than thalidomide.

  • Thalidomide

    Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.Phase 3.

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM, but binds more weakly to Mcl-1 and A1. Phase 1/2.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 1/2.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • YM155 (Sepantronium Bromide)

    YM155 is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 1/2.

Recently Viewed Items

Tags: buy Thalidomide | Thalidomide ic50 | Thalidomide price | Thalidomide cost | Thalidomide solubility dmso | Thalidomide purchase | Thalidomide manufacturer | Thalidomide research buy | Thalidomide order | Thalidomide mouse | Thalidomide chemical structure | Thalidomide mw | Thalidomide molecular weight | Thalidomide datasheet | Thalidomide supplier | Thalidomide in vitro | Thalidomide cell line | Thalidomide concentration | Thalidomide nmr
Contact Us